Coya Therapeutics (NASDAQ:COYA) announced a status update of its investigational regulatory T cell-derived exosome—Treg exosomes—platform for the treatment of systemic and neurodegenerative diseases driven by chronic inflammation.
According to Coya, sustained inflammatory responses caused by dysfunctional immune regulation, is characteristic of serious autoimmune and neurodegenerative diseases.
In a statement, Fred Grossman, DO, CMO of Coya, commented, “Our Treg focused pipeline continues its advancement with the goal of manufacturing an allogeneic specific modality that has the potential to be a first-in-class disease-modifying treatment for devastating neurodegenerative diseases of high unmet need. This approach complements and adds to our pipeline of therapies including COYA-302, that aim to enhance Tregs and suppress neuroinflammation to slow progression in several neurodegenerative diseases.”
Arun Swaminathan, CEO of Coya, added, “We believe Treg exosomes are complementary to and will provide accretive value to our biologics platform. Thanks to our partnership with Dr. Stanley Appel and the Johnson Center, the program is being advanced without impact to our cash runway.”
